WallStSmart

BP PLC ADR (BP)vsNovartis AG ADR (NVS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

BP PLC ADR generates 241% more annual revenue ($193.00B vs $56.58B). NVS leads profitability with a 23.9% profit margin vs 1.7%. BP appears more attractively valued with a PEG of 0.05. BP earns a higher WallStSmart Score of 65/100 (B-).

BP

Strong Buy

65

out of 100

Grade: B-

Growth: 6.0Profit: 5.5Value: 7.3Quality: 5.0

NVS

Buy

51

out of 100

Grade: C-

Growth: 3.3Profit: 9.0Value: 3.3Quality: 5.5
Piotroski: 4/9Altman Z: 1.96
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BPUndervalued (+26.9%)

Margin of Safety

+26.9%

Fair Value

$52.77

Current Price

$43.34

$9.43 discount

UndervaluedFair: $52.77Overvalued
NVSSignificantly Overvalued (-51.8%)

Margin of Safety

-51.8%

Fair Value

$110.12

Current Price

$146.03

$35.91 premium

UndervaluedFair: $110.12Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BP3 strengths · Avg: 9.7/10
PEG RatioValuation
0.0510/10

Growing faster than its price suggests

EPS GrowthGrowth
474.5%10/10

Earnings expanding 474.5% YoY

Market CapQuality
$114.92B9/10

Large-cap with strong market position

NVS5 strengths · Avg: 9.4/10
Market CapQuality
$277.42B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
34.9%10/10

Every $100 of equity generates 35 in profit

Operating MarginProfitability
30.5%10/10

Strong operational efficiency at 30.5%

Profit MarginProfitability
23.9%9/10

Keeps 24 of every $100 in revenue as profit

Free Cash FlowQuality
$2.87B8/10

Generating 2.9B in free cash flow

Areas to Watch

BP4 concerns · Avg: 3.5/10
P/E RatioValuation
36.0x4/10

Premium valuation, high expectations priced in

Price/BookValuation
8.4x4/10

Trading at 8.4x book value

Return on EquityProfitability
5.8%3/10

ROE of 5.8% — below average capital efficiency

Profit MarginProfitability
1.7%3/10

1.7% margin — thin

NVS4 concerns · Avg: 2.5/10
Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

PEG RatioValuation
2.592/10

Expensive relative to growth rate

Revenue GrowthGrowth
-0.7%2/10

Revenue declined 0.7%

EPS GrowthGrowth
-9.3%2/10

Earnings declined 9.3%

Comparative Analysis Report

WallStSmart Research

Bull Case : BP

The strongest argument for BP centers on PEG Ratio, EPS Growth, Market Cap. Revenue growth of 11.6% demonstrates continued momentum. PEG of 0.05 suggests the stock is reasonably priced for its growth.

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.

Bear Case : BP

The primary concerns for BP are P/E Ratio, Price/Book, Return on Equity. Thin 1.7% margins leave little buffer for downturns.

Bear Case : NVS

The primary concerns for NVS are Altman Z-Score, PEG Ratio, Revenue Growth.

Key Dynamics to Monitor

BP profiles as a value stock while NVS is a declining play — different risk/reward profiles.

NVS carries more volatility with a beta of 0.49 — expect wider price swings.

BP is growing revenue faster at 11.6% — sustainability is the question.

NVS generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

BP scores higher overall (65/100 vs 51/100) and 11.6% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

BP PLC ADR

ENERGY · OIL & GAS INTEGRATED · USA

BP plc participates in the energy business globally. The company is headquartered in London, the United Kingdom.

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Want to dig deeper into these stocks?